Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.882
-0.008 (-0.43%)
Jul 28, 2025, 4:00 PM - Market closed
Aprea Therapeutics Stock Forecast
APRE's stock price has decreased by -52.48% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts that cover Aprea Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $15.5, which forecasts a 723.68% increase in the stock price over the next year. The lowest target is $11 and the highest is $20.
Price Target: $15.5 (+723.68%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 15, 2025.
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +962.81% | Jan 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +962.81% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +962.81% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +962.81% | Oct 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +484.55% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
667.08K
from 1.50M
Decreased by -55.60%
Revenue Next Year
612.00K
from 667.08K
Decreased by -8.26%
EPS This Year
-1.48
from -2.35
EPS Next Year
-1.30
from -1.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.9M | 1.9M | 62.2M | ||
| Avg | 667,080 | 612,000 | 20.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.8% | 183.3% | 10,057.7% | ||
| Avg | -55.6% | -8.3% | 3,289.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.96 | -0.77 | 0.16 | ||
| Avg | -1.48 | -1.30 | -0.64 | ||
| Low | -2.45 | -2.19 | -1.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.